These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Cardiovascular Events, Conditions, and Procedures Among People With Episodic Migraine in the US Population: Results from the American Migraine Prevalence and Prevention (AMPP) Study. Buse DC; Reed ML; Fanning KM; Kurth T; Lipton RB Headache; 2017 Jan; 57(1):31-44. PubMed ID: 27861837 [TBL] [Abstract][Full Text] [Related]
4. Potential Channeling Bias in the Evaluation of Cardiovascular Risk: The Importance of Comparator Selection in Observational Research. Li H; Mawanda F; Mitchell L; Zhang X; Goodloe R; Vincent M; Motsko S Pharmaceut Med; 2022 Aug; 36(4):247-259. PubMed ID: 35788962 [TBL] [Abstract][Full Text] [Related]
5. Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies. Roberto G; Raschi E; Piccinni C; Conti V; Vignatelli L; D'Alessandro R; De Ponti F; Poluzzi E Cephalalgia; 2015 Feb; 35(2):118-31. PubMed ID: 25246519 [TBL] [Abstract][Full Text] [Related]
6. Triptan use as a function of cardiovascular risk. A population-based study. Bigal ME; Golden W; Buse D; Chen YT; Lipton RB Headache; 2010 Feb; 50(2):256-63. PubMed ID: 20039953 [TBL] [Abstract][Full Text] [Related]
7. Framingham-Based Cardiovascular Risk Estimates Among People With Episodic Migraine in the US Population: Results from the American Migraine Prevalence and Prevention (AMPP) Study. Lipton RB; Reed ML; Kurth T; Fanning KM; Buse DC Headache; 2017 Nov; 57(10):1507-1521. PubMed ID: 28990165 [TBL] [Abstract][Full Text] [Related]
8. Triptan medication use among patients with migraine with contraindications in the US. Pero A; Pace A; Dhamoon MS Headache; 2022 Jul; 62(7):883-889. PubMed ID: 35670141 [TBL] [Abstract][Full Text] [Related]
9. Acute treatment of migraine: quantifying the unmet need through real-world data in Italy. Sacco S; Di Ciaccio S; Di Virgilio R; Pegoraro V; Ornello R Neurol Sci; 2024 Sep; 45(9):4427-4435. PubMed ID: 38538924 [TBL] [Abstract][Full Text] [Related]
10. Acute treatment patterns in patients with migraine newly initiating a triptan. Lipton RB; Marcus SC; Shewale AR; Dodick DW; Viswanathan HN; Doshi JA Cephalalgia; 2020 Apr; 40(5):437-447. PubMed ID: 32138526 [TBL] [Abstract][Full Text] [Related]
11. Risk of Acute Myocardial Infarction, Heart Failure, and Death in Migraine Patients Treated with Triptans. Ghanshani S; Chen C; Lin B; Duan L; Shen YA; Lee MS Headache; 2020 Nov; 60(10):2166-2175. PubMed ID: 33017476 [TBL] [Abstract][Full Text] [Related]
12. A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication. Lombard L; Farrar M; Ye W; Kim Y; Cotton S; Buchanan AS; Jackson J; Joshi S J Headache Pain; 2020 Apr; 21(1):41. PubMed ID: 32349662 [TBL] [Abstract][Full Text] [Related]
14. Geographic variation in the use of triptans and opioids for the acute treatment of migraine attacks. Lee JH; Shewale AR; Barthold D; Devine B Headache; 2021 Nov; 61(10):1499-1510. PubMed ID: 34841520 [TBL] [Abstract][Full Text] [Related]
15. Triptans and vascular comorbidity in persons over fifty: Findings from a nationwide insurance database - A cohort study. Zebenholzer K; Gall W; Gleiss A; Pavelic AR; Wöber C Headache; 2022 May; 62(5):604-612. PubMed ID: 35593784 [TBL] [Abstract][Full Text] [Related]
16. Triptan use and risk of cardiovascular events: a nested-case-control study from the French health system database. Lugardon S; Roussel H; Sciortino V; Montastruc JL; Lapeyre-Mestre M Eur J Clin Pharmacol; 2007 Aug; 63(8):801-7. PubMed ID: 17576547 [TBL] [Abstract][Full Text] [Related]
17. Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response. Marcus SC; Shewale AR; Silberstein SD; Lipton RB; Young WB; Viswanathan HN; Doshi JA Cephalalgia; 2020 Jun; 40(7):639-649. PubMed ID: 32223301 [TBL] [Abstract][Full Text] [Related]
18. Acute migraine treatment with oral triptans and NSAIDs in a managed care population. Ng-Mak DS; Hu XH; Chen YT; Ma L Headache; 2008 Sep; 48(8):1176-85. PubMed ID: 18819177 [TBL] [Abstract][Full Text] [Related]
19. Health care resource utilization following initiation of a triptan: a retrospective claims analysis. Messali A; Owens G; Bloudek L; Kori S; Cole A; Chia J J Manag Care Spec Pharm; 2014 Apr; 20(4):368-75. PubMed ID: 24684641 [TBL] [Abstract][Full Text] [Related]
20. Factors associated with triptan use in episodic migraine: results from the American Migraine Prevalence and Prevention Study. Chu MK; Buse DC; Bigal ME; Serrano D; Lipton RB Headache; 2012 Feb; 52(2):213-23. PubMed ID: 22413150 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]